Frontotemporal Disorders Treatment Market

Frontotemporal Disorders Treatment Market: Government Initiatives to Advance Neurological Disease Treatments Fuelling Revenue Growth: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028

2018-12-12
REP-GB-5033
213 pages

Home
Market Research Reports
Healthcare, Pharmaceuticals and Medical devices
Frontotemporal Disorders Treatment Market

An Incisive, In-depth Analysis on the Frontotemporal Disorders Treatment Market

This study offers a comprehensive, 360 degree analysis on the Frontotemporal Disorders Treatment market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Frontotemporal Disorders Treatment market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

Request a sample

Ask An Analyst

Request Special Price

Request Methodology

Increasing FTD Drug Development Grants and Funding by Non-Profit Organisations

Non-profit organizations, disease advocacy and private organizations currently are focusing on to support the frontotemporal disorders treatment drug development as the patient base of FTD is expanding. Research funding initiatives by non-profit organization such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, CurePSP, Inc. have helped to promote frontotemporal disorders treatment drugs research initiatives. These organizations support clinical or preclinical studies for testing new therapeutics which are interventional to slow or stop FTD and other neurological disease progression.

Growing Prevalence of Dementia Expected to Propel the Demand for Frontotemporal Disorders Treatment Drugs

Dementia affects around 50 million people globally. Frontotemporal dementia may account for 2–5% of the overall dementia cases. Dementia prevalence is projected to nearly triple by 2050. According to the Dementia Statistics Organization, globally the number of people living with dementia will increase by 204% from 50 Mn in 2018 to 152 Mn in 2050. The growing number of dementia cases will also increase the population base of frontotemporal dementia, which is expected to propel the demand for frontotemporal disorders treatment drugs and medications.

Orphan Drug Development Incentives by FDA Expected to Increase Drug Developer Interest Towards Frontotemporal Disorders Treatment Drug Development

Frontotemporal dementia falls under the rare diseases or orphan indications. FTD affects around 30,000 to 40,000 patients in the U.S. Treatment of FTD falls under the auspices of Orphan Drug Act of 1983 as orphan drug indications are those which affect less than 200,000 people in the U.S. along with similar legislation in the Europe. Orphan drug designation to FTD allows the continuation of clinical trial and drug development with commercial incentives, prioritized consultation by FDA on clinical studies and reduction in regulatory fees.

High Life Expectancy Rate Leads to Higher Prevalence of Frontotemporal Disorders in the Older Age Group

Rising life expectancy rate is another major factor expected to boost the growth of the frontotemporal disorders treatment market due to high prevalence of frontotemporal disorder among the older population. Population aged 65 years and above is mostly prone to neurodegenerative diseases such frontotemporal disorder, Alzheimer and dementia. The global population is projected to increase over the time. Global population in 2015 was around 7.2 Bn and is estimated to grow to around 15 Bn in 2050. People aged 65 and above is one of the fast growing demographics across the globe. Frontotemporal dementia affects around 6.5 people in 100,000 over the age of 65 annually.

Competitive Landscape

This section of the report features profiles of the key players operating in the frontotemporal disorders treatment market based on their market shares, differential strategies, product offerings, marketing approach, and company dashboard. Examples of some of the frontotemporal disorders treatment market key players featured in this report includes Pfizer Inc., Johnson & Johnson, Sanofi S.A., Eli Lilly and Company, GlaxoSmithKline Plc., Novartis AG, Mylan N.V., Merck & Company, Inc., AstraZeneca plc., and Allergen plc, among others. Many companies in the frontotemporal disorders treatment market are aiming on clinical studies and trials for new drug development.

Definition

Frontotemporal disorders are a bunch of rare disorders that include shrinkage of particular portion of the brain, which controls personality, language, and behavior. The condition rises due to degeneration of frontotemporal cells, which are named as frontotemporal lobar degeneration (FTLD). The typical age range for onset of frontotemporal dementia is 40 to 60 years of age, however, it can start after 60 years of age and the maximum life expectancy after diagnosis is 8–10 years.

About the Report

The company conducted a research study on the frontotemporal disorders treatment market for the forecast period 2018 to 2028. The report offers a comprehensive evaluation of the business opportunities prevailing in the frontotemporal disorders treatment market along with insights on the market dynamics, market trend and opportunities, pipeline analysis, disease epidemiology and others. The frontotemporal disorders treatment market report elaborates the macroeconomic factors influencing the dynamics of frontotemporal disorders treatment market and its futuristic potential.

Segmentation

The report offers a comprehensive taxonomy of the frontotemporal disorders treatment market based on drug class, treatment type, disease indication, distribution channel and region. By drug class, the frontotemporal disorders treatment market is segmented into cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and others. By treatment type, the frontotemporal disorders treatment market is segmented into behavioral symptom management and psychological symptoms management segment. By disease indication, the frontotemporal disorders treatment market is segmented into frontotemporal dementia, primary progressive aphasia, and movement disorders segment. By distribution channel, the frontotemporal disorders treatment market is segmented into hospital pharmacies, retail pharmacy, drug stores and online pharmacy. The frontotemporal disorders treatment market has been analyzed across seven regions including North America, Latin America, Western Europe, Eastern Europe, and Asia Pacific excluding Japan (APEJ), Japan and Middle East & Africa (MEA).

Additional Questions Answered

Some of the additional questions addressed in this report on the frontotemporal disorders treatment market-

Who are the key competitors and their product portfolio and strategy in frontotemporal disorders treatment market?
What are major challenges influencing the growth of frontotemporal disorders treatment market?
What are major trends in the frontotemporal disorders treatment market?

Research Methodology

The frontotemporal disorders treatment market has been estimated based on epidemiology-based model and adoption of different symptomatic drugs. The market value was first calculated based on epidemiology of frontotemporal dementia in different region/countries. The frontotemporal disorders treatment market value was estimated based on adoption of different drugs for behavioral and psychological symptoms management, pricing analysis, and epidemiology in top 20 countries globally. Other qualitative factors analyzed are pipeline analysis, regulatory policies, neurological healthcare expenditure related to frontotemporal disorders treatment. This information is further validated with rigorous primary research (including in-person interactions, interviews, surveys and viewpoints of seasoned analysts) and secondary research (including authentic trade journals, verified paid sources and resourceful databases). The research study on frontotemporal disorders treatment market also includes top trends and macro as well as microeconomic factors shaping the frontotemporal disorders treatment market. With this approach, the report on frontotemporal disorders treatment market anticipates the industry attractiveness of every major segment in frontotemporal disorders treatment over the forecast period.

A recent market study published by company – “Frontotemporal Disorders Treatment Market: Global Industry Analysis 2013–2017 & Opportunity Assessment 2018–2028” – consists of a comprehensive assessment of the most important market dynamics. On conducting a thorough research on the historic as well as current growth parameters of the frontotemporal disorders treatment market, growth prospects of the market are obtained with maximum precision. The report features unique and salient factors that may have a huge impact on the development of the frontotemporal disorders treatment market during the forecast period. It can help market players to modify their manufacturing and marketing strategies to envisage maximum growth in the frontotemporal disorders treatment market in the upcoming years. The report provides detailed information about the current and future growth prospects of the frontotemporal disorders treatment market in the most comprehensive way for the better understanding of readers.

Chapter 01 – Executive Summary

The report commences with the executive summary of the frontotemporal disorders treatment market, which includes the summary of key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the frontotemporal disorders treatment market.

Chapter 02 – Market Overview

Readers can find detailed taxonomy and the definition of the frontotemporal disorders treatment market in this chapter, which will help readers to understand the basic information about the frontotemporal disorders treatment outlook and list of key market participants included in the report.

Chapter 03 – Market Dynamics

Readers can find detailed market dynamics of the frontotemporal disorders treatment market in this chapter, which will help readers to understand the basic information about the frontotemporal disorders treatment market dynamics such as drivers, restraints, opportunity and trends included in the report.

Chapter 04 – Key Inclusions

This chapter includes detailed analysis epidemiology of frontotemporal disorders and key regulatory scenario of global frontotemporal disorders treatment market along with region wise assessment.

Chapter 05 – North America Frontotemporal Disorders Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2028

This chapter includes detailed analysis of the growth of the North America frontotemporal disorders treatment market along with the country-wise assessment including the U.S. and Canada. Readers can also find regional trends, regulations, and market growth based drug class, treatment type, diseases indication, distribution channel and countries in the North America frontotemporal disorders treatment market.

Chapter 06 – Latin America Frontotemporal Disorders Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2028

Readers can find detailed information about factors such as regional trends that are impacting the growth of the Latin America frontotemporal disorders treatment market. This chapter also includes the growth prospects of the frontotemporal disorders treatment market in leading LATAM countries such as Brazil, Mexico, and Rest of Latin America.

Chapter 07 – Western Europe Frontotemporal Disorders Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2028

Important growth prospects of the frontotemporal disorders treatment market based on its drug class, treatment type, diseases indication, distribution channel in several Western European countries, such as Germany, the U.K., France, Italy, Spain and rest of Western Europe is included in this chapter.

Chapter 08 – Eastern Europe Frontotemporal Disorders Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2028

Important growth prospects of the frontotemporal disorders treatment market based on its drug class, treatment type, diseases indication, distribution channel in several Eastern European countries, such as Russia, Poland and Rest of Eastern Europe are included in this section.

Chapter 09 – APEJ Frontotemporal Disorders Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2028

India, ASEAN, Japan Australia and New Zealand are the leading countries in the APEJ region that are the prime subject of assessment to obtain growth prospects of the APEJ frontotemporal disorders treatment market in this chapter. Readers can find thorough information about the growth parameters of the APEJ frontotemporal disorders treatment market during the period 2018–2028.

Chapter 10 – Japan Frontotemporal Disorders Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2028

Readers can find important factors that can make a huge impact on the growth of the frontotemporal disorders treatment market in Japan based on the market segmentation, during the forecast period. This chapter provides the overview of regulations, drivers, restraints, and trends in the Japan frontotemporal disorders treatment market.

Chapter 11 – MEA Frontotemporal Disorders Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2028

This chapter provides information on how the frontotemporal disorders treatment market will grow in the major countries in MEA region, such as GCC Countries, South Africa, during the period 2018–2028.

Chapter 12 – Competition Landscape and Company Profiles

In this chapter, readers can find a comprehensive list of all the leading stakeholders in the frontotemporal disorders treatment market along with detailed information about each company, including company overview, revenue shares, strategic overview, and recent company developments. Market players featured in the report includes Pfizer Inc., Johnson & Johnson, Sanofi S.A., Eli Lilly and Company, GlaxoSmithKline Plc., Novartis AG, Mylan N.V., Merck & Company, Inc., AstraZeneca plc., and Allergen plc., among others.

Chapter 13 – Global Frontotemporal Disorders Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2028, By Region

This chapter explains how the frontotemporal disorders treatment market will grow across various geographic regions, such as North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific Excluding Japan (APEJ), Japan, and the Middle East & Africa (MEA).

Chapter 14 – Global Frontotemporal Disorders Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2028, By Drug Class

Based on the drug class, the frontotemporal disorders treatment market is segmented into cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and others. In this chapter, readers can find information about key trends and developments in the frontotemporal disorders treatment market and market attractive analysis based on the drug class.

Chapter 15 – Global Frontotemporal Disorders Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2028, By Treatment Type

Based on the treatment type, the frontotemporal disorders treatment market is segmented into behavioral symptom management and psychological symptoms management segment. In this chapter, readers can find information about key trends and developments in the frontotemporal disorders treatment market and market attractive analysis based on treatment type.

Chapter 16 – Global Frontotemporal Disorders Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2028, By Disease Indication

Based on the disease indication, the frontotemporal disorders treatment market is segmented into frontotemporal dementia, primary progressive aphasia, and movement disorders segment. In this chapter, readers can find information about key trends and developments in the frontotemporal disorders treatment market and market attractive analysis based on disease indication.

Chapter 17 – Global Frontotemporal Disorders Treatment Market Analysis 2013–2017 & Opportunity Assessment 2018–2028, By Distribution Channel

Based on the distribution channel, the frontotemporal disorders treatment market is segmented into hospital pharmacies, retail pharmacy, drug stores, and online pharmacy. In this chapter, readers can find information about key trends and developments in the frontotemporal disorders treatment market and market attractive analysis based on distribution channel.

Chapter 18 – Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.

Chapter 19 – Research Methodology

This chapter helps readers to understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the frontotemporal disorders treatment market.